Comparison · NCT00780962-b8d55b08
N-Acetycysteine Group vs 0.9% Sodium-chloride Group: Number of Participants With Contrast-induced Nephropathy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. N-Acetycysteine Group vs 0.9% Sodium-chloride Group: Number of Participants With Contrast-induced Nephropathy. Trial comparisons, record NCT00780962-b8d55b08. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00780962-b8d55b08
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0757 | 0.0456 | 0.123 | wilson | |
| Risk in group 2 | 0.0698 | 0.0404 | 0.118 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00591 | -0.0509 | 0.0616 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.516 | 2.28 | log | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.49 | 2.43 | log | |
| Number needed to treat, for one more participant with the outcome on N-Acetycysteine Group than on 0.9% Sodium-chloride Group | 169 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | N-Acetycysteine Group | Participants in this group received 3 grams of N-acetylcysteine in 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, participants received a continuous infusion of 200 mg N-acetylcysteine per hour, administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine diluted in a total volume of 1000 cc of normal saline. | 14 | 185 | OG000 |
| Group 2 | 0.9% Sodium-chloride Group | Patients in the placebo group received 500 mL of normal saline solution during 30 minutes before contrast administration and a continuous infusion of 67 mL per hour of normal saline solution after contrast administration | 12 | 172 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Contrast-induced Nephropathy
- Description
Contrast-induced nephropathy was defined as an increase in serum creatinine level of greater than or equal to 0.5 mg/dL or an increase of 25% above baseline. The primary outcome was measured by the change in serum creatinine level from the pre-radiocontrast baseline to the serum creatinine level measured 48 to 72 hours after radiocontrast administration.
- Time frame
- 48-72 hours
- Population
- Out of 399 subjects who consented to participate in the study, only 357 (89.4%) had a second blood creatinine levels measurement done between 48 to 72h.
Source ClinicalTrials.gov
Trial
- Title
- N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients
- NCT number
- NCT00780962
- Phases
- PHASE2
- Conditions
- Radiocontrast Nephropathy
- Interventions
- N-Acetylcysteine (NAC), 0.9% Sodium-chloride
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Results first posted
- 2018-01-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00780962?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00780962-b8d55b08